drugset / Trial / NCT02658396
GO-203-2C + Bortezomib For Relapsed Or Refractory MM
Phase 1
Withdrawn
Dana-Farber Cancer Institute
Genus Oncology, LLC · collabNational Institutes of Health (NIH) · collab
NaSingle-groupOpen-labelTreatment
Summary
This research study is studying a combination of targeted therapies known as GO-203-2C and bortezomib as a possible treatment for multiple myeloma that has either progressed or not responded to treatment.
Timeline
- Start
- —
- Primary completion
- 2019-05
- Completion
- 2022-01
Outcome
Outcome not reported
Stopped (Business): “Study was never open due to lack of funding”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | GO-203-2C | Protein / enzyme biologic | — | — |
| Background | Bortezomib | Small molecule | — | Intravenous |